Skip to content
Study details
Enrolling now

Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

Southwest Autism Research & Resource Center
NCT IDNCT04060030ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

80

Study length

about 5.7 years

Ages

2.5–5

Locations

2 sites in AZ, NY

What this study is about

Researchers are testing whether leucovorin calcium, a medication, helps improve social communication and reduce symptoms in young children with autism spectrum disorder (ASD) who have language delays. The trial will last about 26 weeks and involve approximately 80 children aged 2.5 to 5 years old.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take Levoleucovorin Calcium

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Antidotes, Deterrents, and Toxicologic Agents

Drug routes

injection (Injection)

Endpoints

Primary: Evaluate the change in social communication symptoms

Secondary: Evaluate adverse effect symptoms in young children with ASD, Evaluate change in specific autism symptom severity, Evaluate the change in effects of autism symptoms on family members, Evaluate the change in stereotypical autism symptoms, Evaluate the overall change in core ASD symptoms of social communication, Evaluate the overall change in core ASD symptoms of social communication using a blind observer, Evaluate the safety and tolerability of L-leucovorin calcium in young children with ASD

Body systems

Psychiatry / Mental Health